Advertisement

Mycopathologia

, Volume 183, Issue 3, pp 521–527 | Cite as

Corneal Collagen Cross-Linking for the Management of Mycotic Keratitis

  • Elif Erdem
  • Ibrahim Inan Harbiyeli
  • Hazal Boral
  • Macit Ilkit
  • Meltem Yagmur
  • Reha Ersoz
Original Paper

Abstract

Purpose

To evaluate the efficiency of corneal collagen cross-linking (CXL) in addition to topical voriconazole in cases with mycotic keratitis.

Design

Retrospective case series in a tertiary university hospital.

Participants

CXL was performed on 13 patients with mycotic keratitis who presented poor or no response to topical voriconazole treatment.

Methods

The clinical features, symptoms, treatment results and complications were recorded retrospectively. The corneal infection was graded according to the depth of infection into the stroma (from grade 1 to grade 3). The visual analogue scale was used to calculate the pain score before and 2 days after surgery.

Main Outcome Measures

Grade of the corneal infection.

Results

Mean age of 13 patients (6 female and 7 male) was 42.4 ± 17.7 years (20–74 years). Fungus was demonstrated in culture (eight patients) or cytological examination (five patients). Seven of the 13 patients (54%) were healed with topical voriconazole and CXL adjuvant treatment in 26 ± 10 days (15–40 days). The remaining six patients did not respond to CXL treatment; they initially presented with higher grade ulcers. Pre- and post-operative pain score values were 8 ± 0.8 and 3.5 ± 1, respectively (p < 0.05).

Conclusions

The current study suggests that adjunctive CXL treatment is effective in patients with small and superficial mycotic ulcers. These observations require further research by large randomized clinical trials.

Keywords

Corneal collagen cross-linking Corneal infection Mycotic keratitis Topical voriconazole 

Abbreviations

CXL

Corneal collagen cross-linking

SGA

Sabouraud glucose agar

PDA

Potato dextrose agar

Notes

Compliance with Ethical Standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Prajna NV, Srinivasan M, Lalitha P, et al. Differences in clinical outcomes in keratitis due to fungus and bacteria. JAMA Ophthalmol. 2013;131:1088–9.CrossRefPubMedGoogle Scholar
  2. 2.
    Prajna NV, Mascarenhas J, Krishnan T, et al. Comparison of natamycin and voriconazole for the treatment of fungal keratitis. Arch Ophthalmol. 2010;128:672–8.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Ruane PH, Edrich R, Gampp D, Keil SD, Leonard RL, Goodrich RP. Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light. Transfusion. 2004;44:877–85.CrossRefPubMedGoogle Scholar
  4. 4.
    Reddy HL, Dayan AD, Cavagnaro J, Gad S, Li J, Goodrich RP. Toxicity testing of a novel riboflavin-based technology for pathogen reduction and white blood cell inactivation. Transfus Med Rev. 2008;22:133–53.CrossRefPubMedGoogle Scholar
  5. 5.
    Li Z, Jhanji V, Tao X, Yu H, Chen W, Mu G. Riboflavin/ultraviolet light-mediated crosslinking for fungal keratitis. Br J Ophthalmol. 2013;97:669–71.CrossRefPubMedGoogle Scholar
  6. 6.
    Morén H, Malmsjö M, Mortensen J, Ohrström A. Riboflavin and ultraviolet a collagen crosslinking of the cornea for the treatment of keratitis. Cornea. 2010;29:102–4.CrossRefPubMedGoogle Scholar
  7. 7.
    Anwar HM, El-Danasoury AM, Hashem AN. Corneal collagen crosslinking in the treatment of infectious keratitis. Clin Ophthalmol. 2011;5:1277–80.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Iseli HP, Thiel MA, Hafezi F, Kampmeier J, Seiler T. Ultraviolet A/riboflavin corneal cross-linking for infectious keratitis associated with corneal melts. Cornea. 2008;27:590–4.CrossRefPubMedGoogle Scholar
  9. 9.
    Price MO, Tenkman LR, Schrier A, Fairchild KM, Trokel SL, Price FW. Photoactivated riboflavin treatment of infectious keratitis using collagen cross-linking technology. J Refract Surg. 2012;28:706–13.CrossRefPubMedGoogle Scholar
  10. 10.
    Said DG, Elalfy MS, Gatzioufas Z, et al. Collagen crosslinking with photoactivated riboflavin (PACK-CXL) for the treatment of advanced infectious keratitis with corneal melting. Ophthalmology. 2014;121:1377–82.CrossRefPubMedGoogle Scholar
  11. 11.
    Makdoumi K, Mortensen J, Crafoord S. Infectious keratitis treated with corneal crosslinking. Cornea. 2010;29:1353–8.CrossRefPubMedGoogle Scholar
  12. 12.
    Galperin G, Berra M, Tau J, Boscaro G, Zarate J, Berra A. Treatment of fungal keratitis from Fusarium infection by corneal cross-linking. Cornea. 2012;31:176–80.CrossRefPubMedGoogle Scholar
  13. 13.
    Alio JL, Abbouda A, Valle DD, Del Castillo JM, Fernandez JA. Corneal cross linking and infectious keratitis: a systematic review with a meta-analysis of reported cases. J Ophthalmic Inflamm Infect. 2013;3:47.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Zhang ZY. Corneal cross-linking for the treatment of fungal keratitis. Cornea. 2013;32:217–8.CrossRefPubMedGoogle Scholar
  15. 15.
    Vinciguerra R, Rosetta P, Romano MR, Azzolini C, Vinciguerra P. Treatment of refractory infectious keratitis with corneal collagen cross-linking window absorption. Cornea. 2013;32:139–40.CrossRefGoogle Scholar
  16. 16.
    Vazirani J, Vaddavalli PK. Cross-linking for microbial keratitis. Indian J Ophthalmol. 2013;61:441–4.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Sorkhabi R, Sedgipoor M, Mahdavifard A. Collagen cross-linking for resistant corneal ulcer. Int Ophthalmol. 2013;33:61–6.CrossRefPubMedGoogle Scholar
  18. 18.
    Wollensak G, Spoerl E, Seiler T. Riboflavin/ultraviolet-a-induced collagen crosslinking for the treatment of keratoconus. Am J Ophthalmol. 2003;135:620–7.CrossRefPubMedGoogle Scholar
  19. 19.
    Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis. 2003;36:630–7.CrossRefPubMedGoogle Scholar
  20. 20.
    Sharma S, Das S, Virdi A, et al. Re-appraisal of topical 1% voriconazole and 5% natamycin in the treatment of fungal keratitis in a randomised trial. Br J Ophthalmol. 2015;99:1190–5.CrossRefPubMedGoogle Scholar
  21. 21.
    Sharma N, Agarwal P, Sinha R, Titiyal JS, Velpandian T, Vajpayee RB. Evaluation of intrastromal voriconazole injection in recalcitrant deep fungal keratitis: case series. Br J Ophthalmol. 2011;95:1735–7.CrossRefPubMedGoogle Scholar
  22. 22.
    Kuriakose T, Kothari M, Paul P, Jacob P, Thomas R. Intracameral amphotericin B injection in the management of deep keratomycosis. Cornea. 2002;21:653–6.CrossRefPubMedGoogle Scholar
  23. 23.
    Kumar V, Lockerbie O, Keil SD, et al. Riboflavin and UV-light based pathogen reduction: extent and consequence of DNA damage at the molecular level. Photochem Photobiol. 2004;80:15–21.CrossRefPubMedGoogle Scholar
  24. 24.
    Panda A, Krishna SN, Kumar S. Photoactivated riboflavin therapy of refractory corneal ulcers. Cornea. 2012;31:1210–3.CrossRefPubMedGoogle Scholar
  25. 25.
    Bettis DI, Hsu M, Moshirfar M. Corneal collagen cross-linking for nonectatic disorders: a systematic review. J Refract Surg. 2012;28:798–807.CrossRefPubMedGoogle Scholar
  26. 26.
    Spoerl E, Huhle M, Seiler T. Induction of cross-links in corneal tissue. Exp Eye Res. 1998;66:97–103.CrossRefPubMedGoogle Scholar
  27. 27.
    Dong X, Shi W, Zeng Q, et al. Roles of adherence and matrix metalloproteinases in growth patterns of fungal pathogens in cornea. Curr Eye Res. 2005;30:613–20.CrossRefPubMedGoogle Scholar
  28. 28.
    Spoerl E, Mrochen M, Sliney D, et al. Safety of UVA-riboflavin crosslinking of the cornea. Cornea. 2007;26:385–9.CrossRefPubMedGoogle Scholar
  29. 29.
    Wollensak G, Spoerl E, Wilsch M, et al. Keratocyte apoptosis after corneal collagen cross-linking using riboflavin/UVA treatment. Cornea. 2004;23:43–9.CrossRefPubMedGoogle Scholar
  30. 30.
    Tabibian D, Richoz O, Riat A, et al. Accelerated photoactivated chromophore for keratitis—corneal collagen cross-linking as a first-line and sole treatment in early fungal keratitis. J Refract Surg. 2014;30:855–7.CrossRefPubMedGoogle Scholar
  31. 31.
    Vajpayee RB, Shafi SN, Maharana PK, Sharma N, Jhanji V. Evaluation of corneal collagen cross-linking as an additional therapy in mycotic keratitis. Clin Exp Ophthalmol. 2015;43:103–7.CrossRefPubMedGoogle Scholar
  32. 32.
    Uddaraju M, Mascarenhas J, Ranjan MD, Radhakrishnan N, Keenan JD, Prajna L. Corneal cross-linking as an adjuvant therapy in the management of recalcitrant deep stromal fungal keratitis: a randomized trial. Am J Ophthalmol. 2015;160:131–4.CrossRefPubMedGoogle Scholar
  33. 33.
    Shetty R, Nagaraja H, Jayadev C, et al. Collagen crosslinking in the management of advanced non-resolving microbial keratitis. Br J Ophthalmol. 2014;98:1033–5.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media B.V., part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Ophthalmology, School of MedicineCukurova UniversityAdanaTurkey
  2. 2.Division of Mycology, Department of Microbiology, School of MedicineCukurova UniversityAdanaTurkey

Personalised recommendations